- Home
- MGRX vs VNRX Comparison
MGRX vs VNRX Comparison
Compare MGRX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | VNRX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.2M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MGRX | VNRX |
|---|---|---|
| Price | $0.47 | $0.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.62 |
| AVG Volume (30 Days) | 453.2K | ★ 1.7M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | $456,021.00 | ★ $1,727,384.00 |
| Revenue This Year | N/A | $57.67 |
| Revenue Next Year | N/A | $240.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $0.26 | $0.13 |
| 52 Week High | $2.75 | $3.26 |
Technical Indicators
Market Signals| Indicator | MGRX | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 28.13 |
| Support Level | $0.34 | $0.22 |
| Resistance Level | $0.48 | $0.27 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 54.64 | 24.11 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.